Cargando…
Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689097/ https://www.ncbi.nlm.nih.gov/pubmed/36428923 http://dx.doi.org/10.3390/diagnostics12112864 |
_version_ | 1784836440202412032 |
---|---|
author | Samonis, George Bousmpoukea, Aikaterini Molfeta, Aristea Kalkinis, Antonios D. Petraki, Kalliopi Koutserimpas, Christos Bafaloukos, Dimitrios |
author_facet | Samonis, George Bousmpoukea, Aikaterini Molfeta, Aristea Kalkinis, Antonios D. Petraki, Kalliopi Koutserimpas, Christos Bafaloukos, Dimitrios |
author_sort | Samonis, George |
collection | PubMed |
description | Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary, disorders from the upper GI tract are rare. Such a case of delayed nivolumab induced severe gastritis in a 53-year-old Caucasian female patient suffering metastatic melanoma is described. The patient’s symptoms from the upper GI tract began 4 months after nivolumab treatment initiation. The diagnosis was based on imaging, including PET/CT, endoscopical and pathological findings. The side effect was successfully treated with prolonged administration of proton pump inhibitors and corticosteroids. There are only a few cases of immune check point inhibitors (ICPis) induced upper GI tract disorders, while it seems that the symptoms from nivolumab induced upper GI tract damages appear later than those reported in the lower part. Nivolumab, among other side effects, may cause severe gastritis. Hence, this pathological entity should be included in the list of this drug’s side effects. |
format | Online Article Text |
id | pubmed-9689097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96890972022-11-25 Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient Samonis, George Bousmpoukea, Aikaterini Molfeta, Aristea Kalkinis, Antonios D. Petraki, Kalliopi Koutserimpas, Christos Bafaloukos, Dimitrios Diagnostics (Basel) Case Report Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary, disorders from the upper GI tract are rare. Such a case of delayed nivolumab induced severe gastritis in a 53-year-old Caucasian female patient suffering metastatic melanoma is described. The patient’s symptoms from the upper GI tract began 4 months after nivolumab treatment initiation. The diagnosis was based on imaging, including PET/CT, endoscopical and pathological findings. The side effect was successfully treated with prolonged administration of proton pump inhibitors and corticosteroids. There are only a few cases of immune check point inhibitors (ICPis) induced upper GI tract disorders, while it seems that the symptoms from nivolumab induced upper GI tract damages appear later than those reported in the lower part. Nivolumab, among other side effects, may cause severe gastritis. Hence, this pathological entity should be included in the list of this drug’s side effects. MDPI 2022-11-18 /pmc/articles/PMC9689097/ /pubmed/36428923 http://dx.doi.org/10.3390/diagnostics12112864 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Samonis, George Bousmpoukea, Aikaterini Molfeta, Aristea Kalkinis, Antonios D. Petraki, Kalliopi Koutserimpas, Christos Bafaloukos, Dimitrios Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
title | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
title_full | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
title_fullStr | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
title_full_unstemmed | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
title_short | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
title_sort | severe gastritis due to nivolumab treatment of a metastatic melanoma patient |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689097/ https://www.ncbi.nlm.nih.gov/pubmed/36428923 http://dx.doi.org/10.3390/diagnostics12112864 |
work_keys_str_mv | AT samonisgeorge severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT bousmpoukeaaikaterini severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT molfetaaristea severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT kalkinisantoniosd severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT petrakikalliopi severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT koutserimpaschristos severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT bafaloukosdimitrios severegastritisduetonivolumabtreatmentofametastaticmelanomapatient |